Evofem Biosciences Inc (EVFM) stock is up 12.38% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With EVFM Stock Today?
Evofem Biosciences Inc (EVFM) stock is up 6.1% while the S&P 500 has fallen -0.19% as of 10:10 AM on Thursday, Jun 17. EVFM has risen $0.07 from the previous closing price of $1.11 on volume of 4,032,436 shares. Over the past year the S&P 500 is up 34.91% while EVFM has fallen -61.06%. EVFM lost -$2.34 per share in the over the last 12 months.
To screen for more stocks like Evofem Biosciences Inc click here.
More About Evofem Biosciences Inc
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The company is also evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.
Click Here to get the full Stock Score Report on Evofem Biosciences Inc (EVFM) Stock.
